Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



How Big Is This Risk for Isis Pharmaceuticals, inc. Stock?

Isis Pharmaceuticals (NASDAQ: ISIS  ) has a stable of candidates that companies several times its size would envy. With 32 candidates in development and five likely to be under regulatory review -- or approved -- within the next several years, it might have one of the most efficient discovery engines in the industry.

Now for the bad news, Isis has just one second-generation antisense drug on the market, and so far its launch has been disappointing. While the poor initial reception to Kynamro is upsetting, its performance might be the least of the company's worries. Let's see what is really keeping the RNA antisense pioneer awake at night.

Sinking flagship
Once touted as a potential Lipitor successor by CEO Stanley Crooke, Isis' flagship program, Kynamro, was almost bound to disappoint. While there's little doubt concerning its ability to decrease low density lipoprotein (LDL) cholesterol, serious adverse events prompted the FDA to limit its approval to patients with the extremely rare genetic condition, homozygous familial hypercholesterolemia, or HoFH. The FDA also insisted partners Isis and Sanofi run extensive long-term postmarketing studies to evaluate its long-term safety effects. Across the pond, the EMA refused to recommend its marketing authorization for any population ... twice.

Safety issues aside, Kynamro ran into competition at its outset. In the U.S., Juxtapid from Aegerion Pharmaceuticals won approval for HoFH just a month earlier than Kynamro where it has outperformed. Aegerion booked $48.5 million in Juxtapid sales last year and reached $27 million in the first quarter of 2014. Kynamro's first year sales were dismal enough that neither partner bothered to announce them, although the $3.1 million from licensing activities and royalties that Isis recorded last year suggest they were less than encouraging.

Further pressure for a limited Kynamro market could also be on the way from a new class of LDL cholesterol lowering therapies. Amgen's PCSK9 inhibitor evolocumab recently showed it could decrease LDL cholesterol in HoFH patients by 23% after 12 weeks. Kynamro partner Sanofi is also developing a PCSK9 inhibitor along with Regeneron. While the pair hasn't published HoFH data yet, evolocumab's success could be characteristic of the entire class.

Anti-drug antibodies
Potential cannibalization issues from marketing partner Sanofi might be worth fretting over, but Isis is facing a far more pressing issue. Long-term studies of Kynamro have unveiled serious tolerability issues that could be present across the company's entire pipeline.

Pooled phase 3 trial results showed 37.5% of patients developed antibodies specific to Kynamro. In other words, whenever these patients inject the drug, their immune systems recognize it and to differing degrees attack it. In those phase 3 trials the percentage of patients reporting flu-like symptoms was higher for patients with anti-Kynamro antibodies as for those without, about 25% and 39%, respectively.

Pooled phase 3 data is concerning, but the figures that should have Isis investors shivering come from a longer open-label extension study highlighted at an FDA advisory committee meeting. The data suggests the prevalence of anti-Kynamro antibodies rises as patients remain on therapy. A whopping 72% of patients in the extension study were positive for anti-Kynamro antibodies. Among anti-Kynamro antibody positive patients, over 71% exhibited flu-like symptoms.

Final thoughts
While Kynamro clearly has a host of issues, the main value driver for Isis is its bountiful clinical stage pipeline potentially worth nearly $9 billion per the 10-Q. A healthy stream of milestone revenue could be just waiting for the company's partners to invest moderate sums into clinical development of partnered programs.

Unfortunately that revenue potential won't be worth much if those partners can expect the same long-term tolerability issues present in Kynamro. Now, we don't know right now whether the problems are specific to Kynamro. But if they aren't -- if the antibody formation is a problem generalizable to all drugs in the pipeline -- then Isis could indeed have some additional difficulty.

Risk-free for 30 days: The Motley Fool's flagship service
Tom and David Gardner founded The Motley Fool over 20 years ago with the goal of helping the world invest...better. Their flagship service, Stock Advisor, has helped thousands of investors take control of their financial lives and beat the market. Click here to sign up today.

Read/Post Comments (2) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 29, 2014, at 1:16 PM, FTownBryan wrote:

    Firstly immunogenic responses are common among a whole host of effective and approved drugs and there is no basis to assume that the entire suite of 2.0 candidates will even elicit such responses.

    The supposition could be true, but data from an extension study of one drug in the class provides scant evidence that it is.

    Long ISIS.

  • Report this Comment On July 29, 2014, at 11:51 PM, km00nster wrote:

    Agreed with the comment above. Good luck going into earnings.


Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3039480, ~/Articles/ArticleHandler.aspx, 9/3/2015 11:59:18 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Cory Renauer

Cory is a long-term minded analyst mainly focused on the biotechnology and pharmaceuticals. He genuinely enjoys cutting through the industry's complexities to help everyday investors make better decisions. You can contact Cory on Twitter @coryrenauer

Today's Market

updated 2 hours ago Sponsored by:
DOW 16,374.76 23.38 0.14%
S&P 500 1,951.13 2.27 0.12%
NASD 4,733.50 -16.48 -0.35%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/3/2015 3:59 PM
ISIS $51.57 Down -0.18 -0.35%
Isis Pharmaceutica… CAPS Rating: *****